These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24547986)

  • 1. Gut microbiota and liver disease.
    Goel A; Gupta M; Aggarwal R
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1139-48. PubMed ID: 24547986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.
    Compare D; Coccoli P; Rocco A; Nardone OM; De Maria S; Cartenì M; Nardone G
    Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):471-6. PubMed ID: 22546554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and non-alcoholic fatty liver disease: new insights.
    Aron-Wisnewsky J; Gaborit B; Dutour A; Clement K
    Clin Microbiol Infect; 2013 Apr; 19(4):338-48. PubMed ID: 23452163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota of Nonalcoholic Fatty Liver Disease.
    Abdou RM; Zhu L; Baker RD; Baker SS
    Dig Dis Sci; 2016 May; 61(5):1268-81. PubMed ID: 26898658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
    Wree A; Geisler LJ; Tacke F
    Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctly altered gut microbiota in the progression of liver disease.
    Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
    Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula.
    Yin X; Peng J; Zhao L; Yu Y; Zhang X; Liu P; Feng Q; Hu Y; Pang X
    Syst Appl Microbiol; 2013 May; 36(3):188-96. PubMed ID: 23453736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gut microbiota in health and disease].
    Icaza-Chávez ME
    Rev Gastroenterol Mex; 2013; 78(4):240-8. PubMed ID: 24290319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and liver diseases.
    Minemura M; Shimizu Y
    World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
    Delarue J; Lallès JP
    Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH; DiBaise JK; McClain CJ
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
    Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
    Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance.
    Parnell JA; Raman M; Rioux KP; Reimer RA
    Liver Int; 2012 May; 32(5):701-11. PubMed ID: 22221818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.
    Jiang W; Wu N; Wang X; Chi Y; Zhang Y; Qiu X; Hu Y; Li J; Liu Y
    Sci Rep; 2015 Feb; 5():8096. PubMed ID: 25644696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.